Aurinia alleges that Tidmarsh’s statements were not only inaccurate but also motivated by a personal vendetta against Kevin ...
The resignation of head drug regulator George Tidmarsh comes amid concerns about conduct related to the lupus nephritis drug ...
The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.
A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...
The drama continued Monday with senior FDA leaders as more details emerged about former Center for Drug Evaluation and ...
An alleged extortion attempt, a petty yearslong grudge, shocking social media posts, and ominous text messages make up the ...
Aurinia Pharmaceuticals (AUPH) stock gains as the company's Q3 2025 results beat forecasts despite an FDA information request ...
Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe ...
Dr. George Tidmarsh, who joined the FDA in July, stepped down Sunday, The New York Times reported. His resignation came just ...
The latest turmoil within Commissioner Marty Makary’s Food and Drug Administration, an alleged bribery scandal involving a high-level official, is no anomaly. The Sunday resignation of the Center for ...
Observers characterized the dismissals, policy reversals, and controversies at the FDA as a soap opera, total disarray, and potentially, unprincipled ...
Aurinia Pharmaceuticals (($AUPH)) has held its Q3 earnings call. Read on for the main highlights of the call. Aurinia Pharmaceuticals’ recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback